mRESVIA

Growth

respiratory syncytial virus vaccine

BLAINTRAMUSCULARSUSPENSION
Approved
May 2024
Lifecycle
Growth
Competitive Pressure
30/100
Clinical Trials
9

Clinical Trials (5)

NCT07272434Phase 3Recruiting

Phase III Clinical Trial of the Recombinant Respiratory Syncytial Virus Vaccine ( CHO Cell)

Started Oct 2025
NCT06705140Phase 3Terminated

A Study on the Immunogenicity and Safety of 3 Different Dose Concentrations of a Respiratory Syncytial Virus Vaccine in Infants and Toddlers

Started Nov 2024
947 enrolled
RSV Immunisation
NCT06397768Phase 3Terminated

Co-administration Study of an Investigational Live-Attenuated Respiratory Syncytial Virus Vaccine in Infants and Toddlers

Started May 2024
2,226 enrolled
RSV Immunization
NCT06252285Phase 3Terminated

Efficacy, Immunogenicity, and Safety Study of a Respiratory Syncytial Virus Vaccine in Infants and Toddlers

Started Feb 2024
6,300 enrolled
RSV Immunisation
NCT05687279Phase 1/2Completed

Study on a Live-attenuated Respiratory Syncytial Virus Vaccine for Assessment of Safety, Transmissibility, and Genetic Stability of the Vaccine Virus Among Close Contacts in Infants and Toddlers 6 to < 24 Months of Age in Puerto Rico (USA)

Started Feb 2023
80 enrolled
Respiratory Syncytial Virus Infection